Editorial in today's Providence Journal by Dr.Jerome
Groopman on the cancer discovery at Harvard which has been the rage d' jour.
Groopman writes of his patients calling him at all hours offering themselves
in hopes of being
treated by the "Harvard Cocktail"...(my quotes). His own mother is in
remission in
her fight with breast cancer ..."her voice grew heavy with concern when I
seemed restrained in my enthusiam over the new developments."
"I explainded to my mother, and to my patients...that science rarely leaps
forward with a single epiphany. Rather, it progresses in painstaking
increments, each advance facing a new set of obstacles, some expected and some
unexpected, before
success."
"Human cancers are more diverse, and more adept at becoming resistant to
therapies....furthermore, people might prove allergic to the proteins. Or it
might be hard to sustain adequate amounts of the proteins in the bloodstream
for them to have their desired effect."
"It would be foolhardy for Congress or industry to ignore other research and
look only
to the strategy of blocking blood vessels. The fianancing of science works
like any other investment: Steady returns come with a diversified portfolio."
Dr. Jerome Groopman, professor of medicine at Harvard, also happens to be a
board
member of VIMRX. Groopman has laid out the science, business and future of
cancer research over the next few years....VIMRX, ISOLEX, NEXELL, INNOVIR.
|
